GLP-RT is a breakthrough triple agonist that activates GLP-1, GIP, and glucagon receptors. This unique design has made it one of the most powerful peptides studied for weight management and metabolic health. By targeting three key pathways at once, GLP-RT has provided researchers with an unmatched model for exploring appetite regulation, energy expenditure, and glucose balance. Beyond its physical effects, GLP-1–based research has also uncovered potential links to cognitive performance and neuroprotection, sparking interest in its role across both body and brain.
 
Research Outcomes in Studies:
Phase 2 obesity trial: average weight reductions of up to 24% over 48 weeks.
Significant improvements in insulin sensitivity and glucose control.
Dose-dependent decreases in BMI and waist circumference.
GLP-1 receptor research has shown cognitive and neuroprotective effects in preclinical and early clinical settings.
 
Reference Guide
For deeper research frameworks and pathway explanations, visit The Forge Research Guide.

For laboratory research use only. Not for human or veterinary consumption. Not FDA evaluated.